EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deciphering novel TCF4-driven mechanisms underlying a common triplet repeat expansion-mediated disease

Nihar Bhattacharyya iD, Niuzheng Chai iD, Nathaniel J Hafford-Tear, Amanda N Sadan, Anita Szabo, Christina Zarouchlioti iD, Jana Jedlickova iD, Szi Kay Leung, Tianyi Liao, Lubica Dudakova iD, Pavlina Skalicka, Mohit Parekh iD und 9 weitere

PLOS Genetics · 07.05.2024 · 20 (5) · e1011230

DOI: 10.1371/journal.pgen.1011230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 07.05.2024. Verfasst von Nihar Bhattacharyya und 20 weiteren Autor:innen. Beteiligte Einrichtung: University College London Institute of Ophthalmology, London, United Kingdom. Hauptthemen laut MEDLINE: Fuchs' Endothelial Dystrophy, Transcription Factor 4, Trinucleotide Repeat Expansion. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI, Moorfields Eye Charity, Sight Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fuchs endothelial corneal dystrophy (FECD) is an age-related cause of vision loss, and the most common repeat expansion-mediated disease in humans characterised to date. Up to 80% of European FECD cases have been attributed to expansion of a non-coding CTG repeat element (termed CTG18.1) located within the ubiquitously expressed transcription factor encoding gene, TCF4 . The non-coding nature of the repeat and the transcriptomic complexity of TCF4 have made it extremely challenging to experimentally decipher the molecular mechanisms underlying this disease. Here we comprehensively describe CTG18.1 expansion-driven molecular components of disease within primary patient-derived corneal endothelial cells (CECs), generated from a large cohort of individuals with CTG18.1-expanded (Exp+) and CTG 18.1-independent (Exp-) FECD. We employ long-read, short-read, and spatial transcriptomic techniques to interrogate expansion-specific transcriptomic biomarkers. Interrogation of long-read sequencing and alternative splicing analysis of short-read transcriptomic data together reveals the global extent of altered splicing occurring within Exp+ FECD, and unique transcripts associated with CTG18.1-expansions. Similarly, differential gene expression analysis highlights the total transcriptomic consequences of Exp+ FECD within CECs. Furthermore, differential exon usage, pathway enrichment and spatial transcriptomics reveal TCF4 isoform ratio skewing solely in Exp+ FECD with potential downstream functional consequences. Lastly, exome data from 134 Exp- FECD cases identified rare (minor allele frequency 15) TCF4 variants in 7/134 FECD Exp- cases, suggesting that TCF4 variants independent of CTG18.1 may increase FECD risk. In summary, our study supports the hypothesis that at least two distinct pathogenic mechanisms, RNA toxicity and TCF4 isoform-specific dysregulation, both underpin the pathophysiology of FECD. We anticipate these data will inform and guide the development of translational interventions for this common triplet-repeat mediated disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fuchs' Endothelial DystrophyTranscription Factor 4Trinucleotide Repeat ExpansionHumansMaleAlternative SplicingEndothelial CellsEndothelium, CornealTranscriptomeFemale

Substanzen

TCF4 protein, humanTranscription Factor 4

Autor:innen und Institutionen

  • University College London Institute of Ophthalmology, London, United Kingdom.
  • Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.
  • Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Moorfields Eye Hospital, London, United Kingdom.

ORCID-Profile: Nihar Bhattacharyya, Niuzheng Chai, Christina Zarouchlioti, Jana Jedlickova, Lubica Dudakova, Mohit Parekh, Ismail Moghul, Nikolas Pontikos, Petra Liskova, Stephen J Tuft, Alice E Davidson

Förderung

  • UKRI
  • Moorfields Eye Charity
  • Sight Research UK
  • Rosetrees Trust
  • National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology
  • Grantová Agentura České Republiky
  • Univeristy Research Center
  • Univerzita Karlova v Praze

Zitieren

APA

Bhattacharyya, N., Chai, N., Hafford-Tear, N. J., Sadan, A. N., Szabo, A., Zarouchlioti, C., Jedlickova, J., Leung, S. K., Liao, T., Dudakova, L., Skalicka, P., Parekh, M., Moghul, I., Jeffries, A. R., Cheetham, M. E., Muthusamy, K., Hardcastle, A. J., Pontikos, N., Liskova, P., …, & Davidson, A. E. (2024). Deciphering novel TCF4-driven mechanisms underlying a common triplet repeat expansion-mediated disease. PLOS Genetics, 20(5), e1011230. https://doi.org/10.1371/journal.pgen.1011230

Vancouver

Bhattacharyya N, Chai N, Hafford-Tear NJ, Sadan AN, Szabo A, Zarouchlioti C, et al. Deciphering novel TCF4-driven mechanisms underlying a common triplet repeat expansion-mediated disease. PLOS Genetics. 2024;20(5):e1011230. doi:10.1371/journal.pgen.1011230

BibTeX
@article{Bhattacharyya2024,
  author = {Bhattacharyya, Nihar and Chai, Niuzheng and Hafford-Tear, Nathaniel J and Sadan, Amanda N and Szabo, Anita and Zarouchlioti, Christina and Jedlickova, Jana and Leung, Szi Kay and Liao, Tianyi and Dudakova, Lubica and Skalicka, Pavlina and Parekh, Mohit and Moghul, Ismail and Jeffries, Aaron R and Cheetham, Michael E and Muthusamy, Kirithika and Hardcastle, Alison J and Pontikos, Nikolas and Liskova, Petra and Tuft, Stephen J and Davidson, Alice E},
  title = {Deciphering novel TCF4-driven mechanisms underlying a common triplet repeat expansion-mediated disease},
  journal = {PLOS Genetics},
  year = {2024},
  volume = {20},
  number = {5},
  pages = {e1011230},
  doi = {10.1371/journal.pgen.1011230}
}
Kostenlos starten →